Jose Pacheco, MD
Medical Oncology · Aurora, CONPI 1083935456
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,825 of the $50,084 with a category attached, or 77.5%. 26 manufacturers reported payments, led by AstraZeneca at 40.3% of the total. Reporting peaked in 2019 at $27,857 and has fallen 98.7% since, to $370 in 2025. Among medical oncology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $521.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Pfizer$8K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Blueprint Medicines Corporation$4K
- Sanofi$3K
- Daiichi Sankyo Inc.$2K
- plus $4K from 20 others
Across 56 payments — averaging $14,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$650K
- Gilead$141K
What the payments were for
- Consulting fees$38,82578%
- Speaking & faculty fees$5,15010%
- Travel & lodging$3,3457%
- Food & beverage$2,7646%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $20,188 |
| Pfizer | 8 | $8,494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $7,558 |
| Blueprint Medicines Corporation | 1 | $3,800 |
| Sanofi | 4 | $3,491 |
| Daiichi Sankyo Inc. | 4 | $2,123 |
| Johnson & Johnson | 3 | $2,033 |
| Jazz Pharmaceuticals Inc. | 1 | $1,313 |
| Novartis | 6 | $305 |
| Genentech USA, Inc. | 2 | $170 |
| Merck | 4 | $97 |
| Immunogen, Inc. | 2 | $75 |
| Bristol Myers Squibb | 3 | $63 |
| Tersera Therapeutics LLC | 2 | $60 |
| Amgen | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Boehringer Ingelheim | 1 | $35 |
| Beigene USA, Inc. | 1 | $34 |
| Pharmaessentia USA Corporation | 1 | $25 |
| Exelixis Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Genmab U.S., Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,084 in reported general payments places this provider in the 90th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 11 | $210,996 |
| XareltoRivaroxaban | 56 | $43,917 |
| EliquisApixaban | 40 | $25,398 |
| Anastrozole | 40 | $759 |
| Hydroxyurea | 21 | $603 |
| Prochlorperazine Maleate | 12 | $369 |
| Ondansetron Hcl | 14 | $301 |
| Tamoxifen Citrate | 19 | $294 |
| Warfarin Sodium | 29 | $141 |
| Oxycodone Hcl | 11 | $138 |
| Gabapentin | 19 | $132 |
| Letrozole | 14 | $38 |
| Prednisone | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $305 | $210,99611 claims |
| Johnson & JohnsonXarelto | $2,033 | $43,91756 claims |
| PfizerEliquis | $8,494 | $25,39840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 96 medical oncology providers in Colorado.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
- Christopher LieuAurora$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.